Share Email Print
cover

Proceedings Paper

Spectroscopic imaging system for high-throughput viability assessment of ovarian spheroids or microdissected tumor tissues (MDTs) in a microfluidic chip
Author(s): A. St-Georges-Robillard; M. Masse; J. Kendall-Dupont; M. Strupler; B. Patra; M. Jermyn; A.-M. Mes-Masson; F. Leblond; T. Gervais
Format Member Price Non-Member Price
PDF $14.40 $18.00

Paper Abstract

There is a growing effort in the biomicrosystems community to develop a personalized treatment response assay for cancer patients using primary cells, patient-derived spheroids, or live tissues on-chip. Recently, our group has developed a technique to cut tumors in 350 μm diameter microtissues and keep them alive on-chip, enabling multiplexed in vitro drug assays on primary tumor tissue. Two-photon microscopy, confocal microscopy and flow cytometry are the current standard to assay tissue chemosensitivity on-chip. While these techniques provide microscopic and molecular information, they are not adapted for high-throughput analysis of microtissues. We present a spectroscopic imaging system that allows rapid quantitative measurements of multiple fluorescent viability markers simultaneously by using a liquid crystal tunable filter to record fluorescence and transmittance spectra. As a proof of concept, 24 spheroids composed of ovarian cancer cell line OV90 were formed in a microfluidic chip, stained with two live cell markers (CellTrackerTM Green and Orange), and imaged. Fluorescence images acquired were normalized to the acquisition time and gain of the camera, dark noise was removed, spectral calibration was applied, and spatial uniformity was corrected. Spectral un-mixing was applied to separate each fluorophore's contribution. We have demonstrated that rapid and simultaneous viability measurements on multiple spheroids can be achieved, which will have a significant impact on the prediction of a tumor’s response to multiple treatment options. This technique may be applied as well in drug discovery to assess the potential of a drug candidate directly on human primary tissue.

Paper Details

Date Published: 29 February 2016
PDF: 5 pages
Proc. SPIE 9689, Photonic Therapeutics and Diagnostics XII, 96894E (29 February 2016); doi: 10.1117/12.2211159
Show Author Affiliations
A. St-Georges-Robillard, Ecole Polytechnique de Montréal (Canada)
Ctr. Hospitalier de l'Univ. de Montréal Research Ctr. (Canada)
Institut du cancer de Montreal (Canada)
M. Masse, Ecole Polytechnique de Montréal (Canada)
Ctr. Hospitalier de l'Univ. de Montréal Research Ctr. (Canada)
J. Kendall-Dupont, Ctr. Hospitalier de l'Univ. de Montréal Research Ctr. (Canada)
Institut du Cancer de Montreal (Canada)
M. Strupler, Ecole Polytechnique de Montréal (Canada)
B. Patra, Ecole Polytechnique de Montréal (Canada)
Ctr. Hospitalier de l'Univ. de Montréal Research Ctr. (Canada)
Institut du cancer de Montreal (Canada)
M. Jermyn, McGill Univ. (Canada)
Ecole Polytechnique de Montréal (Canada)
A.-M. Mes-Masson, Ctr. Hospitalier de l'Univ. de Montréal Research Ctr. (Canada)
Institut du Cancer de Montreal (Canada)
Univ. de Montreal (Canada)
F. Leblond, Ecole Polytechnique de Montréal (Canada)
Ctr. Hospitalier de l'Univ. de MontréalResearch Ctr. (Canada)
T. Gervais, Ecole Polytechnique de Montréal (Canada)
Ctr. Hospitalier de l'Univ. de Montréal Research Ctr. (Canada)
Institut du cancer de Montreal (Canada)


Published in SPIE Proceedings Vol. 9689:
Photonic Therapeutics and Diagnostics XII
Hyun Wook Kang; Guillermo J. Tearney; Melissa C. Skala; Bernard Choi; Andreas Mandelis; Brian J. F. Wong; Justus F. Ilgner; Nikiforos Kollias; Paul J. Campagnola; Kenton W. Gregory; Laura Marcu; Haishan Zeng, Editor(s)

© SPIE. Terms of Use
Back to Top